| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:736-743.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
From Baylor College of Medicine (C.M.B., J.A.H., L.L.F., J.K.D., J.A.F., P.H.J.), Houston, Tex; Novartis Pharmaceuticals Corporation (J.R.S.), East Hanover, NJ; and Cornell University Medical College (A.M.G.), New York, NY.
Correspondence to Christie M. Ballantyne, MD, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, TX 77030. E-mail cmb{at}bcm.tmc.edu
Background—Patients with coronary artery disease (CAD) commonly have low HDL cholesterol (HDL-C) and mildly elevated LDL cholesterol (LDL-C), leading to uncertainty as to whether the appropriate goal of therapy should be lowering LDL-C or raising HDL-C.
Methods and Results—Patients in the Lipoprotein and
Coronary Atherosclerosis Study (LCAS) had
mildly to moderately elevated LDL-C; many also had low HDL-C, providing
an opportunity to compare angiographic progression and the benefits of
the HMG-CoA reductase inhibitor fluvastatin in
patients with low versus patients with higher HDL-C. Of the 339
patients with biochemical and angiographic data, 68 had baseline HDL-C
<0.91 mmol/L (35 mg/dL), mean 0.82±0.06 mmol/L (31.7±2.2
mg/dL), versus 1.23±0.29 mmol/L (47.4±11.2 mg/dL) in patients
with baseline HDL-C 
0.91 mmol/L. Among patients on placebo,
those with low HDL-C had significantly more angiographic progression
than those with higher HDL-C. Fluvastatin significantly
reduced progression among low–HDL-C patients: 0.065±0.036 mm
versus 0.274±0.045 mm in placebo patients
(P=0.0004); respective minimum lumen diameter decreases
among higher–HDL-C patients were 0.036±0.021 mm and
0.083±0.019 mm (P=0.09). The treatment effect of
fluvastatin on minimum lumen diameter change was
significantly greater among low–HDL-C patients than among
higher–HDL-C patients (P=0.01); among low–HDL-C
patients, fluvastatin patients had improved event-free
survival compared with placebo patients.
Conclusions—Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit.
Key Words: angiography • cholesterol • coronary disease • drugs • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  J. Z. Willey, Q. Xu, B. Boden-Albala, M. C. Paik, Y. P. Moon, R. L. Sacco, and M. S. V. Elkind Lipid Profile Components and Risk of Ischemic Stroke: The Northern Manhattan Study (NOMAS) Arch Neurol, November 1, 2009; 66(11): 1400 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Miller, C. P. Cannon, S. A. Murphy, J. Qin, K. K. Ray, E. Braunwald, and for the PROVE IT-TIMI 22 Investigators Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 724 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Murao, X. Yu, H. Imachi, W. M. Cao, K. Chen, K. Matsumoto, T. Nishiuchi, N. C. W. Wong, and T. Ishida Hyperglycemia suppresses hepatic scavenger receptor class B type I expression Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E78 - E87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zambon and K. Cusi The role of fenofibrate in clinical practice Diabetes and Vascular Disease Research, September 1, 2007; 4(3_suppl): S15 - S20. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Nogueira and M. Weir The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Steinmetz Lipid-lowering therapy in type 2 diabetes: a review of the evidence Diabetes and Vascular Disease Research, September 1, 2006; 3(1_suppl): S10 - S15. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden 2nd International Symposium on Triglycerides and HDL: Metabolic syndrome Diabetes Care, October 1, 2005; 28(10): 2577 - 2584. [Full Text] [PDF]
|
|
|
|
|
|
F. Espinosa-Larranaga, M. Vejar-Jalaf, and R. Medina-Santillan The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor Diabetes and Vascular Disease Research, October 1, 2005; 2(1_suppl): S1 - S8. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Shepherd Raising HDL-cholesterol and lowering CHD risk: does intervention work? Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F15 - F22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Assmann and A. M. Gotto Jr HDL Cholesterol and Protective Factors in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-8 - III-14. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. F Watts Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses? Eur. Heart J., May 1, 2004; 25(9): 716 - 719. [Full Text] [PDF]
|
|
|
|
|
|
P. P. Toth High-Density Lipoprotein and Cardiovascular Risk Circulation, April 20, 2004; 109(15): 1809 - 1812. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Aspects of Blood Pressure, Lipid, and Glycemic Treatment Diabetes Care, January 1, 2004; 27(1): 264 - 269. [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenberg, H. J. Rupprecht, C. Bickel, X.-C. Jiang, O. Poirier, K. J. Lackner, J.u. Meyer, F. Cambien, L. Tiret, and AtheroGene Investigators Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1983 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, A. G. Olsson, T. J. Cook, M. F. Mercuri, T. R. Pedersen, and J. Kjekshus Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S Circulation, December 18, 2001; 104(25): 3046 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. L. Sacco, R. T. Benson, D. E. Kargman, B. Boden-Albala, C. Tuck, I-F. Lin, J. F. Cheng, M. C. Paik, S. Shea, and L. Berglund High-Density Lipoprotein Cholesterol and Ischemic Stroke in the Elderly: The Northern Manhattan Stroke Study JAMA, June 6, 2001; 285(21): 2729 - 2735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gotto Jr Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease : A Working Group Report Circulation, May 1, 2001; 103(17): 2213 - 2218. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Robins, D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, et al. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: VA-HIT: A Randomized Controlled Trial JAMA, March 28, 2001; 285(12): 1585 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. de Roos, E. G. Schouten, and M. B. Katan Consumption of a Solid Fat Rich in Lauric Acid Results in a More Favorable Serum Lipid Profile in Healthy Men and Women than Consumption of a Solid Fat Rich in trans-Fatty Acids J. Nutr., February 1, 2001; 131(2): 242 - 245. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Chen, U. Ikeda, M. Shimpo, M. Ikeda, S. Minota, and K. Shimada Fluvastatin Upregulates Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Vascular Smooth Muscle Cells Hypertension, December 1, 2000; 36(6): 923 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, J. A. Herd, E. A. Stein, L. L. Ferlic, J. K. Dunn, A. M. Gotto Jr., and A. J. Marian Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1572 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Vicari, G. J. Wan, A. M. Aura, C. M. Alexander, L. E. Markson, S. M. Teutsch, and for the Simvastatin Combined Hyperlipidemia Regist Use of Simvastatin Treatment in Patients With Combined Hyperlipidemia in Clinical Practice Arch Fam Med, September 1, 2000; 9(9): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Jacobson, G. G. Griffiths, C. Varas, D. Gause, J. C. Y. Sung, and C. M. Ballantyne Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data Arch Intern Med, May 8, 2000; 160(9): 1361 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Marian, F. Safavi, L. Ferlic, J. K. Dunn, A. M. Gotto, and C. M. Ballantyne Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study J. Am. Coll. Cardiol., January 1, 2000; 35(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Corsini Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 161 - 175. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Lutucuta, C. M. Ballantyne, H. Elghannam, A. M. Gotto Jr, and A. J. Marian Novel Polymorphisms in Promoter Region of ATP Binding Cassette Transporter Gene and Plasma Lipids, Severity, Progression, and Regression of Coronary Atherosclerosis and Response to Therapy Circ. Res., May 11, 2001; 88(9): 969 - 973. [Abstract] [Full Text] [PDF]
|
|